The Technical Analyst
Ventyx Biosciences, Inc. [VTYX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Ventyx Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.89% $4.71
America/New_York / 6 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 332.05 mill |
| EPS: | -3.30 |
| P/E: | -1.430 |
| Earnings Date: | Mar 25, 2024 |
| SharesOutstanding: | 70.50 mill |
| Avg Daily Volume: | 4.11 mill |
| RATING 2024-05-06 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.430 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.24x |
| Company: PE -1.430 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.667 (-85.83%) $-4.04 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.16 - 5.26 ( +/- 11.72%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-12 | Subramaniam Somu | Sell | 695 339 | Common Stock |
| 2024-04-12 | Nsv Partners Iii Lp | Sell | 695 339 | Common Stock |
| 2024-04-02 | Krueger Christopher W | Sell | 1 651 | Common Stock |
| 2024-04-02 | Nuss John | Sell | 1 651 | Common Stock |
| 2024-04-02 | Mohan Raju | Sell | 4 312 | Common Stock |
| INSIDER POWER |
|---|
| -9.42 |
| Last 100 transactions |
| Buy: 2 083 814 | Sell: 2 354 020 |
Forecast:
16:00 - $4.71
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.71
Forecast 2: 16:00 - $4.71
Forecast 3: 16:00 - $4.71
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.71 (-2.89% ) |
| Volume | 0.434 mill |
| Avg. Vol. | 4.11 mill |
| % of Avg. Vol | 10.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VTYX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $2.35 | N/A | Active |
|---|
VTYX
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Last 10 Buy Signals
Latest Press Releases
2024-05-02 16:05:00 - Press Release
Ventyx Biosciences To Report First Quarter 2024 Financial Results On May 9, 2024
San diego, may 02, 2024 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx), (“ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended march 31, 2024 after market close on may 9, 2024. company management will host a conference call and webcast beginning at 4:30 p.m. et/ 1:30 p.m. pt that day to discuss the financial results and highlight recent pipeline and business progress.
2024-04-30 14:15:00 - Press Release
April 30, 2024 Deadline: Contact Levi & Korsinsky To Join Class Action Suit Against Vtyx
New york, ny / accesswire / april 30, 2024 / if you suffered a loss on your ventyx biosciences, inc. (nasdaq:vtyx) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77625&wire=1 or contact joseph e. levi, esq.
2024-04-30 13:31:00 - Press Release
Vtyx Deadline Today: Rosen, Recognized Investor Counsel, Encourages Ventyx Biosciences, Inc. Investors To Secure Counsel Before Important April 30 Deadline In Securities Class Action - Vtyx
New york , april 30, 2024 /prnewswire/ -- why: rosen law firm, a global investor rights law firm, reminds purchasers of common stock of ventyx biosciences, inc. (nasdaq: vtyx): (i) pursuant and/or traceable to the offering documents issued in connection with the company's october 21, 2021 initial public offering (the "ipo" or "offering"); and/or securities (ii) between october 21, 2021 and november 6, 2023, both dates inclusive (the "class period"), of the important april 30, 2024 lead plaintiff deadline. so what: if you purchased ventyx securities during the class period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
2024-04-30 12:45:00 - Press Release
Class Action Filed Against Ventyx Biosciences, Inc. (vtyx) Seeking Recovery For Investors - Contact Levi & Korsinsky
New york, ny / accesswire / april 30, 2024 / if you suffered a loss on your ventyx biosciences, inc. (nasdaq:vtyx) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77617&wire=1 or contact joseph e. levi, esq.
2024-04-30 11:00:00 - Press Release
Shareholders That Lost Money On Ventyx Biosciences, Inc.(vtyx) Urged To Join Class Action - Contact Levi & Korsinsky To Learn More
New york, ny / accesswire / april 30, 2024 / if you suffered a loss on your ventyx biosciences, inc. (nasdaq:vtyx) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77602&wire=1 or contact joseph e. levi, esq.
Latest News
2024-05-02 16:05:00 - GlobeNewsWire
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
2024-04-30 13:00:31 - Zacks Investment Research
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
Ventyx Biosciences (VTYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-11-09 11:19:14 - Zacks Investment Research
Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround
Ventyx Biosciences, Inc. (VTYX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-11-07 11:45:16 - Seeking Alpha
Ventyx Biosciences Now Has 2 Strikes
Today, we look at Ventyx Biosciences, Inc., a clinical-stage biopharma company focused on developing small molecule products for inflammatory diseases. The company has now had two major trial disappointments in the span of a month, triggering a huge selloff in the shares. However, the company's pipeline still has a few "shots on goal" and the stock is now trading below net cash on the balance sheet.
2023-11-07 08:47:10 - InvestorPlace
Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?
Ventyx Biosciences (NASDAQ: VTYX ) stock is falling hard on Tuesday after the clinical-stage biopharmaceutical company released poor study results. These results come from a Phase 2 clinical trial of VTX958 in patients suffering from moderate to severe plaque psoriasis.
2023-11-07 07:15:00 - Market Watch
Ventyx Biosciences' stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target
Shares of Ventyx Biosciences Inc. VTYX, -9.56% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaque psoriasis and psoriatic arthritis treatments. The stock, which was the biggest decliner listed on major U.S. exchanges ahead of the open, was on track to suffer a record one-day selloff and open in record-low territory.
2023-10-11 12:47:26 - Zacks Investment Research
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-severely active ulcerative colitis. Stock down.
2023-10-10 12:55:00 - The Motley Fool
Why Shares of Ventyx Biosciences Are Dropping Tuesday
Ventyx is a clinical-stage biotech that focuses on autoimmune disorders. The company's lead therapy candidate is VTX002 to treat moderate-to-severe ulcerative colitis.
2023-08-30 16:05:00 - GlobeNewsWire
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
2023-08-13 11:11:02 - Seeking Alpha
Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:23 PM ET Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q2 2023 Earnings Conference Call August 10, 2023, 16:30 PM ET Company Participants Raju Mohan - Founder and CEO Marty Auster - CFO Bill Sandborn - President and Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Alex Thompson - Stifel Vikram Purohit - Morgan Stanley Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright Sam Slutsky - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Second Quarter 2023 Earnings Conference Call.